Asia Pacific allergy

https://doi.org/10.5415/apallergy.2016.6.4.207 Asia Pac Allergy 2016;6:207-212

The ingestion of cow's milk formula in the first 3 months of life prevents the development of cow's milk allergy

Tetsuhiro Sakihara^{1,2,*}, Shiro Sugiura¹, and Komei Ito¹

¹Department of Allergy, Aichi Children's Health and Medical Center, Obu 474-8710, Japan ²Department of Pediatrics, Heartlife Hospital, Okinawa 901-2492, Japan

Background: IgE-mediated cow's milk allergy (CMA) is one of the most common food allergies in infants. It is still controversial whether the early introduction of cow's milk formula (CMF) prevents the development of CMA.

Objective: We aimed to evaluate the duration and frequency of CMF ingestion as compere with exclusive breast-fed for preventing CMA in high-risk infants.

Methods: We enrolled the patients diagnosed with hen's egg allergy by an oral food challenge. A questionnaire was completed by the caregivers of the patients regarding the timing of introduction and discontinuation of CMF, and the frequency of CMF ingestion. Based on the information, we analyzed the relationship between the duration and frequency of CMF ingestion and the development of CMA at 3–24 months of age.

Results: Three hundred seventy-four patients were analyzed; 171 were diagnosed with CMA (45.7%). The analyzed patients (n = 374) were categorized into the following subgroups: exclusively breast-fed (breast-fed group, n = 75); discontinued ingestion of CMF before 3 months of age (temporary group, n = 177); continuous ingestion of CMF, but not daily, up to 3 months of age (nondaily group, n = 47); continuous ingestion of CMF at least once daily (daily group, n = 75). The incidence of developing CMA between the breast-fed group and temporary group did not show any statistical difference. Nondaily group and daily group had significantly lower incidence of developing CMA in comparison to the breast-fed group (nondaily group odds ratio 0.43; p = 0.02, daily group odds ratio 0.11; p < 0.001).

Conclusion: Ingestion of CMF during the first 3 months of life might prevent the development of CMA in high-risk infants.

Key words: Food allergy; Milk allergy; Immunoglobulin E; Infant formula; Breast feeding

Correspondence: Tetsuhiro Sakihara Department of Allergy, Aichi Children's Health and Medical Center, 7-426, Morioka, Aichi, Obu 474-8710, Japan Tel: +81-562-43-0500 Fax: +81-562-43-0513 E-mail: odekorin2000@yahoo.co.jp

Received: June 24, 2016 **Accepted:** October 7, 2016 This is an Open Access article distributed under the terms of the Creative Commons Attribution. Non-Commercial License (http://creativecommons. org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © 2016. Asia Pacific Association of Allergy, Asthma and Clinical Immunology.

INTRODUCTION

IgE-mediated cow's milk allergy (CMA) is one of the most common food allergies in infants and children. Its estimated prevalence is 1.9%–4.9% [1]. CMA is thought to run its course in most patients within the first year of life [2]. In Japan, the most of neonates stay in maternity hospitals for one week after birth. Some neonates were given cow's milk formula (CMF) in maternity hospitals then discontinued CMF after discharge. We often recognize that some of them develop CMA with introduction of baby food containing cow's milk protein (CMP).

A prospective population-based birth cohort demonstrated that exclusive breast feeding is associated with reduced risk of CMP sensitization [3]. Some systematic reviews showed that highrisk infants who were exclusively breast fed for at least 4 months had a lower risk of CMA than those who received CMF [4-7]. Furthermore, the enquiring about tolerance (EAT) study showed that early introduction of milk dose not have any significant effects on developing CMA [8]. In contrast, the previous study showed that the early introduction of CMF reduced the frequency of CMA [9]. Although this study focused on the relationship of early introduction of CMF and development of CMA, the duration and frequency of CMF ingestion were not evaluated. Therefore, we aimed to evaluate the duration and frequency of CMA in high-risk infants.

MATERIALS AND METHODS

We enrolled the patients diagnosed with hen's egg allergy by an oral food challenge (OFC) at the Aichi Children's Health and Medical Center (ACHMC) at ≤6 years of age from March 2012 to August 2015. The baseline characteristics of the subjects, perinatal information, coexisting chronic disease, atopic dermatitis in infancy, bronchial asthma before 2 years of age, family history of allergic diseases and information related to the diagnosis of CMA were obtained from the patients' medical records. These variables were adjusted for statistical analyses.

A questionnaire was completed by the caregivers of patients from September to December 2015 regarding the timing of the introduction and discontinuation of CMF (within the first week of life, from the first week to 1 month, and from 1 to 3 months), and the frequency of CMF ingestion (at least once daily, 2–4 days per week, ≤1 day per week). We did not account hydrolyzed formulas as CMF, and no participants were fed amino acid formula. We also checked the subjects' feeding status in infancy from the initial medical record and the maternal and child health handbook to reduce the recall bias and misclassification.

The diagnostic criteria of CMA for patients was to have both following conditions; (1) a positive OFC result or any convincing episode of immediate reaction within 2 hours after the ingestion of a cow's milk product and (2) positive cow's milk-specific IgE (CM-slgE, >0.34 KU_A/L). The concentration of specific IgE antibody was measured from sera using ImmunoCAP system (Thermo Fisher Diagnostics, Tokyo, Japan).

Based on the information, we analyzed the relationship between the duration and frequency of CMF ingestion in the first 3 months of life and the development of CMA at 3–24 months of age. We also evaluated the maximum CM-slgE titer and the achievement of tolerance at <72 months of age. In this research, we regarded patients as who achieved tolerance according to the capability of quantity cow's milk ingestion (100 mL/dose for <36 months of age, 200 mL/dose for ≥36 months of age) with no symptoms.

All statistical analyses were performed using the EZR software program (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [10]. This retrospective data analysis was approved by the institutional ethical committee of ACHMC.

RESULTS

Three hundred ninety-seven of the 520 potential eligible patients (positive egg OFC) came to the hospital for a follow-up examination within the study period (Fig. 1). Twenty-three of the 397 patients were excluded for the following reasons: incomplete questionnaires (n = 11), underlying diseases (n = 2), developing CMP-induced enterocolitis syndrome (n = 1), and developing CMA before 3 months of age (n = 9). No significant difference was observed in the baseline characteristics of the excluded patients and the analyzed patients except the maximum total IgE and egg white-specific IgE titers (Table 1).

The analyzed patients were categorized into the following subgroups: exclusively breast fed (breast-fed group, n = 75); discontinued ingestion of CMF before 3 months of age (temporary group, n = 177); continuous ingestion of CMF, but not daily, up to 3 months of age (nondaily group, n = 47); continuous



Fig. 1. The study recruitment and categorization of analyzed patients. We enrolled the patients diagnosed with hen's egg allergy by an oral food challenge at the Aichi Children's Health and Medical Center at ≤ 6 years of age from March 2012 to August 2015. A questionnaire was completed by the caregivers of patients from September to December 2015 regarding the timing of the introduction and discontinuation of cow's milk formula (CMF) (within the first week of life, from the first week to 1 month, and from 1 to 3 months), and the frequency of CMF ingestion (at least once daily, 2–4 days per week, ≤ 1 day per week). The analyzed patients were categorized into the following subgroups: exclusively breast feeding (breast-fed group); discontinued ingestion of CMF before 3 months of age (temporary group); continuous ingestion of CMF, but not daily, up to 3 months of age (nondaily group); continuous ingestion of CMF at least once daily (daily group). CMA, cow's milk allergy.

Variable	Enrolled population $(n = 520)$	Excluded patients (n = 146)	Analyzed patients (n = 374)	Odds ratio	<i>p</i> -value
Male sex	345 (66.3)	101 (69.2)	244 (65.2)	0.84	NS
Preterm	26 (5.0)	5 (3.4)	21 (5.6)	1.68	NS
Low birth weight	37 (7.1)	10 (6.8)	27 (7.2)	1.06	NS
Atopic dermatitis	396 (76.2)	114 (78.1)	282 (75.4)	0.86	NS
Bronchial asthma	120 (23.1)	31 (21.2)	89 (23.8)	1.16	NS
Family history	473 (91.0)	128 (87.7)	345 (92.2)	1.67	NS
Total IgE (IU/mL)	557 (200–1,458)	361 (132–910)	646 (242–1,679)	-	< 0.001*
EW-sIgE (U _A /mL)	29.4 (10.6–78.3)	20.0 (7.03–60.8)	33.3 (13.2–91.3)	-	0.002*
CMA incidence	224 (43.1)	53 (36.3)	171 (45.7)	1.48	NS
CM-sIgE (U _A /mL) [†]	29.7 (9.98–100)	33.5 (10.7–78.6)	29.7 (9.94–100)	-	NS
Persistent-CMA [†]	103 (46.0)	19 (35.8)	84 (49.1)	1.73	NS

Table 1. Baseline characteristics between excluded and analyzed patients

Values are presented as number (%) or median (interquartile range). Mann-Whitney *U*-test or chi-squate test or Fisher exact test, as appropriate for comparisons. Family history, family history of allergic diseases; total IgE, maximum total IgE titer at <72 months of age; EW-sIgE, maximum egg white-specific IgE titer at <72 months of age; CMA, cow's milk allergy; CM-sIgE, maximum cow's milk-specific IgE titer at <72 months of age; NS, nonsignificant. *p < 0.05, statistically significant. [†]Analysis for CMA patients.

Asia Pacific allergy

ingestion of CMF at least once daily (daily group, n = 75) (Fig. 1). One hundred seventy-one patients (45.7%) were diagnosed as CMA after 3 months of age.

The incidence of developing CMA between the breastfed group and temporary group did not show any statistical difference. However, nondaily group and daily group had a significantly lower incidence of developing CMA in comparison to the Breast-fed group (nondaily group odds ratio, 0.43; p = 0.02; daily group odds ratio, 0.11; p < 0.001) (Table 2). In the multivariate logistic regression analysis, the ingestion of CMF at least once daily until the first 3 months of age was independently associated with the lower incidence of developing CMA (adjusted odds ratio, 0.16; p < 0.001) (Table 3). However, we did not detect obvious relationship between CMF ingestion and the maximum CM-slgE titer or the achievement of tolerance (Table 2).

DISCUSSION

The recent publication of randomized trials suggested that

early oral exposure to food antigen induces tolerance [8, 11]. The learning early about peanut allergy study showed that a lower ratio of peanut-specific IgG4:IgE was associated with peanut allergy [11]. In our study, the daily group had a significantly lower incidence of developing CMA in comparison to the breastfed group whereas the incidence of developing CMA in the temporary group did not have statistical difference. Additional prospective cohorts should be needed to evaluate the elevation and transplacental transport of cow's milk specific IgG4. EAT study performed early-introduction of multiple allergenic foods including CMP from 3 months of age in an unselected population of exclusively breastfed infants. Furthermore, the ingestion of CMP was nondaily. As a result, no significant effect of earlyintroduction of CMP to prevent CMA was demonstrated [8].

In our study, we selected the patients with confirmed hen's egg allergy as a high-risk group and evaluated the development of comorbid CMA. The relatively high CMA comorbidity (45.7%) in the subjects was due to the highly specialized role of our institute where complicated cases tend to be consulted from the local pediatricians. The result demonstrated that high-risk infants

Variable	Breast-fed group (n = 75)	Temporary group (n = 177)		Nondaily group (n = 47)		Daily group (n = 75)				
	Value	Value	OR	<i>p</i> -value	Value	OR	<i>p</i> -value	Value	OR	<i>p</i> -value
Male sex	48 (64.0)	111 (62.7)	0.96	NS	31 (66.0)	1.09	NS	54 (72.0)	1.45	NS
Preterm	0 (0)	7 (3.9)	-	-	3 (6.4)	-	-	11 (14.7)	-	-
Low birth weight	4 (5.3)	11 (6.2)	1.18	NS	3 (6.4)	1.21	NS	9 (12)	2.42	NS
Atopic dermatitis	61 (81.3)	131 (74.0)	0.65	NS	35 (74.5)	0.67	NS	55 (73.3)	0.63	NS
Bronchial asthma	15 (20.0)	45 (25.4)	1.36	NS	10 (21.3)	1.08	NS	19 (25.3)	1.36	NS
Family history	70 (93.3)	162 (91.5)	0.77	NS	43 (91.5)	0.77	NS	70 (93.3)	1.00	NS
Total IgE (IU/mL)	748 (386–1,559)	639 (186–1,719)	-	NS	832 (242–2,098)	-	NS	519 (317–1,099)	-	NS
EW-slgE (U _A /mL)	41.4 (14.7–94.8)	31.6 (10.7–93.1)	-	NS	39.1 (21.6–87.7)	-	NS	23.1 (11.1–75.0)	-	NS
CMA incidence	46 (61.3)	95 (53.6)	0.75	NS	19 (40.4)	0.43	0.02	11 (14.7)	0.11	< 0.001*
Diagnosed with OFC^{\dagger}	22 (48)	44 (46)	0.94	NS	12 (63)	1.87	NS	6 (55)	1.31	NS
CM-sIgE $(U_A/mL)^{\dagger}$	58.0 (14.6–100)	24.7 (7.04–100)	-	NS	45.1 (14.5–100)	-	NS	23.2 (8.77–46.4)	-	NS
Persistent-CMA [†]	24 (52.2)	48 (50.5)	0.92	NS	8 (42.1)	0.67	NS	4 (36.4)	0.52	NS

Table 2. Background and the incidence of cow's milk allergy in the designated four groups according to the ingestion of cow's milk formula

Values are presented as number (%) or median (interquartile range). Mann-Whitney *U*-test or chi-square test or Fisher exact test, as appropriate for comparisons. Bonferroni correction (significance level 0.033) was performed, as appropriate, for multiple comparisons.

OR, odds ratio; family history, family history of allergic diseases; total IgE, maximum total IgE titer at <72 months of age; EW-sIgE, maximum egg whitespecific IgE titer at <72 months of age; CMA, cow's milk allergy; OFC, oral food challenge; Diagnosed with OFC, diagnosed with positive cow's milk oral food challenge test result; CM-sIgE, maximum cow's milk-specific IgE titer at <72 months of age; NS, nonsignificant.

* *p* < 0.001. [†]Analysis for CMA patients.

Variable	CMA (n = 171)	Non-CMA (n = 203)	aOR	95% CI	<i>p</i> -value
Male sex	114 (66.7)	130 (64.0)	1.20	0.75–1.93	NS
Preterm	3 (1.8)	18 (8.9)	0.18	0.04-0.80	0.024*
Low birth weight	11 (6.4)	16 (7.9)	1.58	0.53-4.69	NS
Cesarean section	20 (11.7)	38 (18.7)	0.83	0.43–1.61	NS
Atopic dermatitis	138 (80.7)	144 (70.9)	1.40	0.82-2.37	NS
Bronchial asthma	48 (28.1)	41 (20.2)	1.52	0.89–2.59	NS
Family history	158 (92.4)	187 (92.1)	1.01	0.44-2.32	NS
EW-sIgE >50 U _A /mL	80 (46.8)	65 (32.0)	1.61	1.01–2.58	0.044*
Daily CMF ingestion [†]	11 (6.4)	64 (31.5)	0.16	0.08-0.32	<0.001*

Table 3. The multivariate logistic regression analysis of the risk factors for the development of cow's milk allergy

Values are presented as number (%).

CMA, cow's milk allergy; aOR, adjusted odds ratio; CI, confidence interval; family history, family history of allergic diseases; EW-slgE, maximum egg whitespecific IgE titer at <72 months of age; CMF, cow's milk formula; NS, nonsignificant.

 $p^* < 0.05$, statistically significant. [†]CMF ingestion at least once daily until first 3 months of age.

who ingested CMF daily up to 3 months of age showed lower frequency of developing CMA compared to the high-risk infants with exclusive breast feeding. Although a similar finding has previously been reported [9], this is the first report to suggest the duration and frequency-dependent effect of CMF ingestion in the prevention of CMA.

Eleven patients of the daily group (14.7%) developed CMA. Most of them were predominantly breast-fed and added small amount of CMF. Some of them had allergic reaction when they intake a large amount of CMP such as cheese for the first time (data not shown). This suggests that the amount of CMF ingestion might also be considered to evaluate the effect and risk of early ingestion of CMF.

Traditionally, it was thought that CMA was resolved by 1 to 2 years of age. However, Carroccio et al. [12] found the proportions of Italian infants with CMA who achieved tolerance at 1, 2, and 3 years after initiation of milk-free diets were 30%, 54%, and 70%, respectively. Vanto et al. [13] also showed the proportions of Finnish infants with CMA who achieved tolerance at 2, 3, and 4 years of age were 31%, 53%, and 63%, respectively. The rates of persistent CMA in our study (49.1% at 5 years of age) were similar to these findings. When comparing the prevalence of persistent CMA between the groups, there were no significant differences. From this result, early introduction of CMF may affect the onset of CMA while the achievement of tolerance may be associated by re-introduction of CMP after diagnosis of CMA.

The temporary group included nine patients who changed

CMF to hydrolyzed formula before 3 months of age. The reasons of starting hydrolyzed formula were the instruction by their maternity hospital (n = 4), diarrhea (n = 1), eczema (n = 2), and eczema with positive CM-slgE (n = 2). Three of the last 4 patients with eczema developed CMA afterward.

Katz et al. [14] demonstrated that the cumulative incidence for CMP-induced enterocolitis syndrome was 0.34% in a large-scale, population-based prospective study. In our study, one of the patients developed CMP-induced enterocolitis syndrome (0.2%), yet no patient was diagnosed as cow's milk intolerance.

The limitation of our study was due to its retrospective style. The possibility of reverse causation was minimized by excluding the cases which developed CMA before the age of 3 months. Although we checked the feeding records in the initial medical record and a patients' maternal and child health handbook, a recall bias regarding to the feeding status in infancy might be inevitable. Another limitation is the highly selected subjects (confirmed egg allergy as high-risk infants), so the result cannot be generalized to the normal populations.

The advantage of breast feeding in providing essential nutrients and immunomodulatory effects has been noted in many studies. In this research, most of the patients with CMF ingestion started with mixed feeding, and discontinued CMF afterward. So, the result does not deny the advantage of breast feeding. Additional prospective cohorts should be needed to confirm this observation.

ACKNOWLEDGEMENTS

This study was partially supported by the Practical Research Project for Allergic Disease and Immunology from the Japan Agency for Medical Research and Development (AMED).

REFERENCES

Asia Pacific

- Fiocchi A, Brozek J, Schünemann H, Bahna SL, von Berg A, Beyer K, Bozzola M, Bradsher J, Compalati E, Ebisawa M, Guzmán MA, Li H, Heine RG, Keith P, Lack G, Landi M, Martelli A, Rancé F, Sampson H, Stein A, Terracciano L, Vieths S; World Allergy Organization (WAO) Special Committee on Food Allergy. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines. Pediatr Allergy Immunol 2010;21 Suppl 21:1-125.
- Høst A, Halken S, Jacobsen HP, Christensen AE, Herskind AM, Plesner K. Clinical course of cow's milk protein allergy/intolerance and atopic diseases in childhood. Pediatr Allergy Immunol 2002;13 Suppl 15:23-8.
- Liao SL, Lai SH, Yeh KW, Huang YL, Yao TC, Tsai MH, Hua MC, Huang JL; PATCH (The Prediction of Allergy in Taiwanese Children) Cohort Study. Exclusive breastfeeding is associated with reduced cow's milk sensitization in early childhood. Pediatr Allergy Immunol 2014;25:456-61.
- Fleischer DM, Spergel JM, Assa'ad AH, Pongracic JA. Primary prevention of allergic disease through nutritional interventions. J Allergy Clin Immunol Pract 2013;1:29-36.
- Greer FR, Sicherer SH, Burks AW; American Academy of Pediatrics Committee on Nutrition; American Academy of Pediatrics Section on Allergy and Immunology. Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics 2008;121:183-91.

- Høst A, Halken S, Muraro A, Dreborg S, Niggemann B, Aalberse R, Arshad SH, von Berg A, Carlsen KH, Duschén K, Eigenmann PA, Hill D, Jones C, Mellon M, Oldeus G, Oranje A, Pascual C, Prescott S, Sampson H, Svartengren M, Wahn U, Warner JA, Warner JO, Vandenplas Y, Wickman M, Zeiger RS. Dietary prevention of allergic diseases in infants and small children. Pediatr Allergy Immunol 2008;19:1-4.
- Kramer MS, Kakuma R. Optimal duration of exclusive breastfeeding. Cochrane Database Syst Rev 2012;(8):CD003517.
- Perkin MR, Logan K, Tseng A, Raji B, Ayis S, Peacock J, Brough H, Marrs T, Radulovic S, Craven J, Flohr C, Lack G; EAT Study Team. Randomized trial of introduction of allergenic foods in breast-fed infants. N Engl J Med 2016;374:1733-43.
- Katz Y, Rajuan N, Goldberg MR, Eisenberg E, Heyman E, Cohen A, Leshno M. Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy. J Allergy Clin Immunol 2010;126:77-82.e1.
- 10. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013;48:452-8.
- Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, Brough HA, Phippard D, Basting M, Feeney M, Turcanu V, Sever ML, Gomez Lorenzo M, Plaut M, Lack G; LEAP Study Team. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 2015;372:803-13.
- Carroccio A, Montalto G, Custro N, Notarbartolo A, Cavataio F, D'Amico D, Alabrese D, Iacono G. Evidence of very delayed clinical reactions to cow's milk in cow's milk-intolerant patients. Allergy 2000;55:574-9.
- Vanto T, Helppilä S, Juntunen-Backman K, Kalimo K, Klemola T, Korpela R, Koskinen P. Prediction of the development of tolerance to milk in children with cow's milk hypersensitivity. J Pediatr 2004;144:218-22.
- Katz Y, Goldberg MR, Rajuan N, Cohen A, Leshno M. The prevalence and natural course of food protein-induced enterocolitis syndrome to cow's milk: a large-scale, prospective population-based study. J Allergy Clin Immunol 2011;127:647-53.e1-3.